Pembrolizumab monotherapy showed promising antitumor activity for patients with high-risk non–muscle invasive bladder cancer that did not respond to standard treatment with BCG.
Medscape Medical News
Pembrolizumab Activity in BCG-Refractory Papillary Bladder Cancer
